What is Leqembi and how does it work?
Who is eligible for Leqembi treatment?
How is Leqembi administered?
What are the potential side effects and monitoring requirements?
Leqembi is a monoclonal antibody treatment for early-stage Alzheimer’s disease. It works by targeting and reducing amyloid plaques in the brain, potentially helping to slow cognitive decline in patients with mild cognitive impairment or mild dementia.
Leqembi is for patients with early-stage Alzheimer’s disease, specifically mild cognitive impairment or mild dementia. Patients must have confirmed elevated beta-amyloid in the brain through testing like PET scans or spinal fluid analysis.
Leqembi is given as an IV infusion every two weeks at a healthcare facility. Each session requires medical supervision and regular monitoring by healthcare professionals.
The most common side effects of LEQEMBI include infusion-related reactions, ARIA, and headaches.
